Similar to imatinib, sunitinib was also tested in a phase II trial in 13 patients with ACC of salivary glands and 11 of these achieved stable disease; however, the investigators did not test the patients’ tumors for KIT or PDGFR expression [41]. This evidence concerns the gene PDGFRB and adrenal cortex carcinoma.